Last $30.20 USD
Change Today 0.00 / 0.00%
Volume 0.0
As of 8:10 PM 01/5/15 All times are local (Market data is delayed by at least 15 minutes).

stada arzneimittel ag (STDAF) Snapshot

Open
$30.20
Previous Close
$30.20
Day High
$30.20
Day Low
$30.20
52 Week High
02/26/14 - $50.35
52 Week Low
01/5/15 - $30.20
Market Cap
1.8B
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
60.6M
EX-Date
06/5/14
P/E TM
--
Dividend
$0.80
Dividend Yield
2.89%
Current Stock Chart for STADA ARZNEIMITTEL AG (STDAF)

Related News

No related news articles were found.

stada arzneimittel ag (STDAF) Related Businessweek News

No Related Businessweek News Found

stada arzneimittel ag (STDAF) Details

STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of active pharmaceutical ingredients for the health care and pharmaceutical markets worldwide. The company operates primarily in two segments, Generics and Branded Products. The Generics segment provides various active ingredients, including stomach medicines, antihypertensive agents, and anti-inflammatory agents. This segment’s primarily products include Phospholipide, a liver medicine; Diclofenac, an antirheumatic drug; Tilidine, an opioid; Enalapril, an ACE inhibitor; and Omeprazole, a stomach medicine. The Branded Products segment offers non-prescription products, such as Grippostad and Ladival. This segment’s products also comprise Apo-Go, a Parkinson medicine; Snup, a nasal preparation; Zaldiar, a pain medicine; Chondroxid for the treatment of degenerative joint diseases; and Ladival, a sun cream. The company has license and collaboration agreements with Gedeon Richter Plc for the development and marketing of biosimilar products for two monoclonal antibodies rituximab and optionally trastuzumab. It serves patients and/or consumers, doctors, doctors’ cooperatives, pharmacies, pharmacy co-operatives, hospitals, wholesalers, and other service providers in the health care market, as well as public health insurance organizations or private insurances. STADA Arzneimittel Aktiengesellschaft was founded in 1895 and is headquartered in Bad Vilbel, Germany.

9,825 Employees
Last Reported Date: 03/26/14
Founded in 1895

stada arzneimittel ag (STDAF) Top Compensated Officers

Chairman of the Executive Board and Chief Exe...
Total Annual Compensation: €3.2M
Chief Financial Officer and Member of Executi...
Total Annual Compensation: €1.4M
Chief Business Development & Central Services...
Total Annual Compensation: €844.6K
Compensation as of Fiscal Year 2013.

stada arzneimittel ag (STDAF) Key Developments

Stada-Arzneimittel AG Presents at UniCredit und Kepler Cheuvreux 14th German Corporate Conference, Jan-19-2015 10:45 AM

Stada-Arzneimittel AG Presents at UniCredit und Kepler Cheuvreux 14th German Corporate Conference, Jan-19-2015 10:45 AM. Venue: Villa Kennedy, Kennedyallee 70, D-60596 Frankfurt, Germany. Speakers: Helmut Kraft, Chief Financial Officer and Member of Executive Board.

Stada-Arzneimittel AG Presents at Oddo Midcap Forum, Jan-08-2015 through Jan-09-2015

Stada-Arzneimittel AG Presents at Oddo Midcap Forum, Jan-08-2015 through Jan-09-2015. Venue: Lyon’s Convention Center, Lyon, France. Presentation Date(s): Jan-08-2015. Jan-09-2015.

Stada Reportedly Sells Storage Operations To DHL

Stada-Arzneimittel AG (DB:SAZ) has reportedly sold its storage operations to DHL International GmbH for an undisclosed price.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
STDAF:US $30.20 USD 0.00

STDAF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BTG PLC 808.50 GBp +5.00
Richter Gedeon Nyrt 3,789 +14.00
Oxford Biomedica PLC 6.85 GBp -0.82
Skyepharma PLC 251.00 GBp -7.25
Vernalis PLC 50.38 GBp +0.88
View Industry Companies
 

Industry Analysis

STDAF

Industry Average

Valuation STDAF Industry Range
Price/Earnings 11.3x
Price/Sales 0.7x
Price/Book 1.5x
Price/Cash Flow 11.2x
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact STADA ARZNEIMITTEL AG, please visit www.stada.de. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.